MARKET

GRAY

GRAY

GRAYBUG VISION, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.370
0.000
0.00%
Opening 10:10 01/27 EST
OPEN
1.400
PREV CLOSE
1.370
HIGH
1.460
LOW
1.370
VOLUME
5.03K
TURNOVER
--
52 WEEK HIGH
35.18
52 WEEK LOW
1.260
MARKET CAP
26.24M
P/E (TTM)
-0.7987
1D
5D
1M
3M
1Y
5Y
We Think Graybug Vision (NASDAQ:GRAY) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 12/06/2021 10:40
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fr...
GlobeNewswire · 11/15/2021 21:05
Graybug Vision EPS misses by $0.01
Graybug Vision (NASDAQ:GRAY): Q3 GAAP EPS of -$0.38 misses by $0.01. Revenue of $0M Press Release
Seekingalpha · 11/11/2021 21:34
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Benzinga · 11/08/2021 13:24
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 11/08/2021 12:56
Graybug Vision Reports Analysis Of Data From Six-Month Extension Study Of The ALTISSIMO Phase 2b Trial In Wet AMD
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness 73% reduction of injection burden for
Benzinga · 09/28/2021 11:31
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients participating in Extension StudyGB-102 1mg continued to indi...
GlobeNewswire · 09/28/2021 11:30
Enveric Biosciences and Cellect Biotechnology among healthcare gainers; Forte Biosciences among losers
Gainers: Cellect Biotechnology (NASDAQ:APOP) +39%. NeuroOne Medical Technologies (NASDAQ:NMTC) +17%. Enveric Biosciences (NASDAQ:ENVB) +16%. Impel NeuroPharma (NASDAQ:IMPL) +12%. Progenity (NASDAQ:PROG) +10%. Losers: Forte Biosciences (NASDAQ:FBRX) -81%. E...
Seekingalpha · 09/03/2021 14:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRAY. Analyze the recent business situations of GRAYBUG VISION, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
20.00%Buy
80.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GRAY stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.
High6.00
Average4.500
Low3.000
Current 1.370
EPS
Actual
Estimate
-1.10-0.83-0.55-0.28
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 28
Institutional Holdings: 11.21M
% Owned: 58.49%
Shares Outstanding: 19.16M
TypeInstitutionsShares
Increased
3
6.60K
New
4
328.88K
Decreased
12
587.82K
Sold Out
17
283.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.98%
Pharmaceuticals & Medical Research
+1.76%
Key Executives
Non-Executive Chairman/Independent Director
Christy Shaffer
President/Chief Executive Officer/Director
Frederic Guerard
Chief Financial Officer
Robert Breuil
Chief Technology Officer
Daniel Salain
Other
Parisa Zamiri
Independent Director
Christina Ackermann
Independent Director
Eric Bjerkholt
Independent Director
Gerald Cagle
Independent Director
Julie Eastland
No Data
  • All
  • Financials
  • Insiders
More
About GRAY
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The Company's lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD) and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

Webull offers kinds of Graybug Vision Inc stock information, including NASDAQ:GRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRAY stock methods without spending real money on the virtual paper trading platform.